😀🇦🇹 multisociety (gastroenterology & hepatology, diabetology & obesity) consensus on MASLD (& MetALD!)
🤝Well-aligned with @easlnews.bsky.social CPGs
😟Reimbursement currently restricted to semaglutide for T2DM
🤔Reimbursement in your country?

🖇️: rdcu.be/eLAde

#LiverSky @georg-semmler.bsky.social

Overview on published/presented data on MASH cirrhosis #LiverSky @bavenocoop.bsky.social

🖇️: authors.elsevier.com/sd/article/S...

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)

👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3

🖇️ for explanation: authors.elsevier.com/sd/article/S...

📰Disease-modifying effect of efruxifermin in compensated cirrhosis due to MASH: To miss the forest for the tree(s)

👉Cirrhosis regression only partially captures the potential therapeutic benefit of disease-modifying drugs in phase 3

🖇️ for explanation: authors.elsevier.com/sd/article/S...

@bavenocoop.bsky.social visiting the Japanese Society of Portal Hypertension

👀 at our auditorium

🙏 incredible hospitality

👉 See our 🇯🇵 friends at Baveno VIII

Adéu Jaume, GOAT of portal hypertension! What a loss!

I remember how privileged I felt when he visited Hemodinámica Hepática in 2019 and picked me up for lunch at Paco Meralgo.

Our last walk in Bern this Spring ...

👏
Standing ovations for @bavenocoop.bsky.social's @docberza.bsky.social at the @easlnews.bsky.social Community Award presentation.
Chapeau! What a wonderful person!
#LiverSky

Thirteen years ago when I was still an M.D. student, I was invited for my first oral presentation at an @easlnews.bsky.social event.
🙏 to EASL for inspiration, education & support throughout this journey as well as to my mentors & friends! @bavenocoop.bsky.social #LiverSky

‼️Following first hepatic decompensation, patients with severe #AATD have a higher risk of complications vs. other aetiologies
👉Early listing for liver transplantation. #LiverSky

🔗https://doi.org/10.1016/j.jhepr.2024.101308

@easlnews.bsky.social @jhepatology.bsky.social

Have you ever screened 25 patients for a single trial and randomized nearly as many?

Vienna Hepatic Hemodynamic Lab advancing drug development for portal hypertension. Eager to see results ...

#LiverSky @bavenocoop.bsky.social

@bavenocoop.bsky.social Research Committee Baveno VIII Pre-Symposium, here we go!
👍 103 members watching online
👉 High interest in designing clinical studies on PH.
#liversky

❤️ @easlnews.bsky.social & @bavenocoop.bsky.social friends

I had the privilege to visit two top liver destinations in 🇪🇺 in the last couple of days - 🙏 enormous hospitality
🇨🇭Bern @docberza.bsky.social et al
🇮🇹Padova Alberto Zanetto et al
👀Summary slides attached!
#liversky

Challenge for #liversky :
Monitoring regression/progression on resmetirom & deciding on alternative treatments
▶️ AASLD provided guidance
▶️ We commented on the role of LSM: doi.org/10.1097/HEP....
‼️ Random variation in LSM >25%
‼️ Consider overall medical benefit (e.g., GLP-1)

👋 Bluesky

📰 Review: Non-invasive assessment of portal hypertension: Liver stiffness and beyond

@docberza.bsky.social & @juanabraldes.bsky.social summarising the evidence for the upcoming @bavenocoop.bsky.social VIII in @jhepatology.bsky.social Reports

🔗https://doi.org/10.1016/j.jhepr.2024.101300